Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA(R) (aflibercept) Injection for Patients with Wet AMD

TARRYTOWN, N.Y., Dec. 11, 2017 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics Licen... Biopharmaceuticals, Ophthalmology, FDA Regeneron Pharmaceuticals, EYLEA, aflibercept, macular degeneration

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2043272

Source: HSMN NewsFeed - December 11, 2017 Category: Pharmaceuticals Source Type: news

More News: Food and Drug Administration (FDA) | Marketing | Opthalmology